Sustained high trough factor IX activity levels with continued use of rIX-FP in adult and paediatric patients with haemophilia B

Haemophilia. 2019 May;25(3):e219-e222. doi: 10.1111/hae.13735. Epub 2019 Mar 13.

Authors

Joan C Gill¹, John Roberts², Yanyan Li², Giancarlo Castaman^{3

4}

Affiliations

¹ Blood Research Institute, Blood Center of Wisconsin, Medical College of Wisconsin, Children's Research Institute, Milwaukee, Wisconsin.
² CSL Behring, King of Prussia, Pennsylvania.
³ Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, Italy.
⁴ Department of Cell Therapy and Hematology, Hemophilia and Thrombosis Center, San Bortolo Hospital, Vicenza, Italy.

No abstract available

Publication types

Letter

MeSH terms

Adolescent
Adult
Child
Factor IX / metabolism*
Factor IX / therapeutic use
Female
Hemophilia B / drug therapy*
Hemophilia B / metabolism*
Humans
Male
Recombinant Fusion Proteins / therapeutic use*
Serum Albumin / therapeutic use*
Time Factors
Treatment Outcome

Substances

Recombinant Fusion Proteins
Serum Albumin
Factor IX
albutrepenonacog alfa

Grants and funding

CSL Behring